Cancer DNA blood test study halted before it began

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility Criteria * Men or women who have a diagnosis of histological confirmed EBC (stage I, II or III) of any histopathology and any subtype (hormone-receptor positive or negative, HER2-positive, or negative). * Have tumor tissue available of sufficient quality for processing by Myriad Genetics. * Participant must be willing to provide serial blood samples at specific timepoints specific for each subgroup of interest per the Schedule of Activities * Age ≥18 years at enrollment * Arm A: Participants undergoing neoadjuvant systemic therapy: those with newly diagnosed untreated EBC of any subtype, stage I-II-II, who are scheduled to receive neoadjuvant systemic therapy of any type (i.e. chemotherapy, targeted therapy, immunotherapy, endocrine therapy) including a combination of agents, prior to undergoing breast surgery * Arm B: Participants with TNBC or HER2-positive EBC (T1a, T1b, N0): those with newly diagnosed and untreated TNBC or HER2-positive EBC who have a plan to undergo upfront breast surgery as part of their standard of care treatment * Arm C: Participants who receive an adjuvant CDK4/6-inhibitor (i.e., abemaciclib or ribociclib): those who have a diagnosis of hormone-receptor positive, HER2-negative, stage I-II-III EBC who have a plan to receive adjuvant abemaciclib or adjuvant ribociclib as part of their standard of care treatment * Arm D: Participants who receive an adjuvant PARP-inhibitor (i.e., olaparib): those who have a germline pathogenic mutation (i.e. BRCA) and a diagnosis of hormone-receptor positive or negative, HER2-negative, stage I-II-III EBC, and have a plan to receive an adjuvant PARPinhibitor as part of their standard of treatment plan * Arm E: Participants who develop ipsilateral locoregional recurrence (ILRR): those who have a diagnosis of EBC of any subtype, stage I-II-II and have completed local therapy (i.e. breast surgery and/or radiation therapy) and develop biopsy-proven locoregional disease recurrence in the ipsilateral breast and/or ipsilateral regional nodal basins * Arm F: Participants who completed local therapy and are 5 or more years out from breast surgery: those who have a diagnosis of EBC of any subtype, stage I-II-II, and have completed local therapy (i.e. breast surgery and/or radiation therapy), and are 5 or more years out from local therapy and do not have clinical evidence of disease Exclusion Criteria * Participants with distant cancer metastases (beyond locoregional disease recurrence) * Participants with cognitive impairment/psychiatric illness/social situations that would limit compliance with study requirements. * Current or recent (within the last year) diagnosis of another primary malignancy (except skin cancer and non-invasive cancer) * Personal history of allogenic bone marrow or organ transplant * Participants who are pregnant